



COMPANY OVERVIEW

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company's head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.

RECENT NEWS

[Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis](#)

May 10 2021, 4:05 PM EDT

STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	1.44b
Last Price	\$11.23
52-Week Range	\$10.03 - \$20.50

05/11/2021 04:00 PM EDT

INVESTOR RELATIONS

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate
Communications and Investor Relations
IR@auriniapharma.com

MANAGEMENT TEAM

Peter Greenleaf

Chief Executive Officer, Director

Max Colao

Chief Commercial Officer

Max Donley, MBA

Executive Vice President, Operations and Strategy

Robert Huizinga, Ph.D., R.N., CNeph(C)

Executive Vice President of Research

Michael Martin

Chief Business Officer

Joe Miller

Chief Financial Officer

Stephen Robertson

Executive Vice President, General Counsel,
Corporate Secretary & Chief Compliance
Officer

Neil Solomons, M.D.

Chief Medical Officer

AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Canada

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.